These Analysts Increase Their Forecasts On Danaher Following Upbeat Q3 Earnings

Core Insights - Danaher Corporation reported third-quarter adjusted earnings of $1.89 per share, exceeding analyst expectations of $1.72 per share by 9.82% and up from $1.71 per share in the same quarter last year [1] - The company achieved quarterly revenue of $6.05 billion, surpassing analyst expectations of $6.01 billion [1] Financial Performance - The third-quarter results were positively influenced by strong execution in the DBS-driven strategy, growth in the bioprocessing business, and better-than-expected respiratory revenue at Cepheid [2] - Danaher maintained its full-year 2025 adjusted earnings guidance of $7.70 to $7.80 per share, compared to estimates of $7.78 per share, and expects core revenue growth in the low-single digits for full-year 2025 [2] Market Reaction - Following the earnings announcement, Danaher shares fell 0.4% to trade at $219.87 [3] - Analysts adjusted their price targets for Danaher, with Barclays raising its target from $225 to $250 and TD Cowen increasing its target from $250 to $260, both maintaining positive ratings [5]